Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease

• Main Authors: Jongyoon Shinn (Author), Juyeon Lee (Author), Seon Ah Lee (Author), Seon Ju Lee (Author), Ah Hyun Choi (Author), Jung Seo Kim (Author), Su Jin Kim (Author), Hyo Jin Kim (Author), Cherin Lee (Author), Yejin Kim (Author), Joohyeon Kim (Author), Jonghee Choi (Author), Byungchae Jung (Author), Taeho Kim (Author), HyeonTaek Nam (Author), Hyungjun Kim (Author), Yonghyun Lee (Author)
• Format: Book
• Published: MDPI AG, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointest...